Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes

Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes

Background and Aim: Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the leading indication for liver transplant and is associated with increased cardiovascular and liver mortality, yet there are no licensed therapies. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used fo...

Full description

Bibliographic Details
Main Authors:	Marjot, T, Green, CJ, Charlton, CA, Cornfield, T, Hazlehurst, J, Moolla, A, White, S, Francis, J, Neubauer, S, Cobbold, JFL, Hodson, L, Tomlinson, JW
Format:	Journal article
Language:	English
Published:	Wiley 2019

Similar Items

Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis
by: Green, CJ, et al.
Published: (2022)

Of mice and men: is there a future for metformin in the treatment of hepatic steatosis?
by: Green, C, et al.
Published: (2018)

Non-alcoholic fatty liver disease in adults: Current concepts in etiology, outcomes and management
by: Marjot, T, et al.
Published: (2019)

Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital
by: Marjot, T, et al.
Published: (2017)

Non-alcoholic fatty liver disease and diabetes.
by: Hazlehurst, J, et al.
Published: (2016)

Acute intermittent hypoxia drives hepatic de novo lipogenesis in humans and rodents
by: Hazlehurst, JM, et al.
Published: (2022)

Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
by: Mathew John, et al.
Published: (2016-01-01)

Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions
by: Sanjay Kalra, et al.
Published: (2015-01-01)

Sex differences in hepatic de novo lipogenesis with acute fructose feeding
by: Low, W, et al.
Published: (2018)

Using total plasma triacylglycerol to assess hepatic de novo lipogenesis as an alternative to VLDL triacylglycerol
by: Hodson, L, et al.
Published: (2020)

Dissociation between liver fat content and fasting metabolic markers of selective hepatic insulin resistance in humans
by: Westcott, F, et al.
Published: (2024)

Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis
by: Albert Macaire C. Ong Lopez, et al.
Published: (2024-01-01)

Effect of sodium‐glucose cotransporter 2 inhibitor canagliflozin on interstitial glucose concentration in insulin‐treated diabetic dogs
by: Jessica R. Box, et al.
Published: (2024-05-01)

The Neuronal and Non-Neuronal Pathways of Sodium-Glucose Cotransporter-2 Inhibitor on Body Weight-Loss and Insulin Resistance
by: Dong M, et al.
Published: (2023-02-01)

The sodium–glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes
by: Tsuyoshi Okura, et al.
Published: (2022-02-01)

Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
by: A. M. Mkrtumyan, et al.
Published: (2021-09-01)

Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions
by: Habib Yaribeygi, et al.
Published: (2023-01-01)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
by: Xiaoya Sun, et al.
Published: (2022-12-01)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
by: Jun Tang, et al.
Published: (2022-02-01)

Acute intermittent hypoxia drives hepatic de novo lipogenesis in humans and rodents
by: Jonathan M. Hazlehurst, et al.
Published: (2022-06-01)

Mechanisms of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure
by: Jiangjun Wei, et al.
Published: (2023-04-01)

An exanthematous drug eruption with sodium‐glucose cotransporter 2 inhibitor
by: Ryu Fukase, et al.
Published: (2024-01-01)

The Rate of Adverse Events of Sodium-Glucose Cotransporter 2 Inhibitors:
by: Omar Sajdeya
Published: (2023-05-01)

Bibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
by: He Sun, et al.
Published: (2023-01-01)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
by: Fan Yang, et al.
Published: (2020-12-01)

Effect of the sodium‐glucose cotransporter‐2 inhibitor, DWP16001, as an add‐on therapy to insulin for diabetic dogs: A pilot study
by: Ju‐Hyun An, et al.
Published: (2024-05-01)

The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
by: Ioana-Cristina Bica, et al.
Published: (2023-06-01)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
by: Munteanu Madalina Andreea, et al.
Published: (2023-04-01)

Sodium Chloride Cotransporter in Hypertension
by: Annalisa Castagna, et al.
Published: (2024-11-01)

Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on insulin: a network meta-analysis
by: M. V. Shestakova, et al.
Published: (2025-01-01)

Sodium-glucose cotransporter-2 inhibitors for improving endocrine and metabolic profiles in overweight and obese individuals with polycystic ovary syndrome: a meta-analysis protocol
by: Bing He, et al.
Published: (2022-04-01)

Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Weight Reduction in Overweight and Obese Populations without Diabetes: A Systematic Review and a Meta-Analysis
by: Yun Kyung Cho, et al.
Published: (2021-12-01)

Treatment of Heart Failure with Sodium-glucose Cotransporter Type 2 Inhibitors
by: Riber Fabián Donoso Noroña, et al.
Published: (2024-09-01)

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
by: Habib Yaribeygi, et al.
Published: (2023-04-01)

Effectiveness and safety of sodium–glucose cotransporter 2 inhibitors in Asian populations
by: Kyoung Hwa Ha, et al.
Published: (2024-03-01)

Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition
by: Aviram Kogot-Levin, et al.
Published: (2023-04-01)

Sodium-glucose cotransporter 2 inhibitors in Asian patients with heart failure
by: Shingo Kato, et al.
Published: (2023-04-01)

Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure
by: Ting-Wei Kao, et al.
Published: (2022-12-01)